These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 24440599)

  • 21. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Goparaju R; Schwarzer A; Görlich K; Schottmann R; Struys EA; Jansen EE; Rohde C; Müller-Tidow C; Geffers R; Göhring G; Ganser A; Thol F; Heuser M
    Leukemia; 2016 Aug; 30(8):1708-15. PubMed ID: 27063596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
    Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
    Issa GC; DiNardo CD
    Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
    Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
    J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair.
    Chen TC; Yao CY; Chen YR; Yuan CT; Lin CC; Hsu YC; Chuang PH; Kao CJ; Li YH; Hou HA; Chou WC; Tien HF
    Oncogene; 2022 Mar; 41(11):1576-1588. PubMed ID: 35091680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
    Wang GG; Pasillas MP; Kamps MP
    Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.
    Novak RL; Harper DP; Caudell D; Slape C; Beachy SH; Aplan PD
    Exp Hematol; 2012 Dec; 40(12):1016-27. PubMed ID: 22885519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear factor of activated T-cells, NFATC1, governs FLT3
    Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
    J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
    Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
    Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
    Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
    Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH1 and IDH2 mutations in pediatric acute leukemia.
    Andersson AK; Miller DW; Lynch JA; Lemoff AS; Cai Z; Pounds SB; Radtke I; Yan B; Schuetz JD; Rubnitz JE; Ribeiro RC; Raimondi SC; Zhang J; Mullighan CG; Shurtleff SA; Schulman BA; Downing JR
    Leukemia; 2011 Oct; 25(10):1570-7. PubMed ID: 21647154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.
    Morishima T; Takahashi K; Chin DWL; Wang Y; Tokunaga K; Arima Y; Matsuoka M; Suda T; Takizawa H
    Cancer Sci; 2024 Jan; 115(1):197-210. PubMed ID: 37882467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia.
    Weisberg SP; Smith-Raska MR; Esquilin JM; Zhang J; Arenzana TL; Lau CM; Churchill M; Pan H; Klinakis A; Dixon JE; Mirny LA; Mukherjee S; Reizis B
    Cell Rep; 2014 Feb; 6(3):528-40. PubMed ID: 24485662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HOX expression patterns identify a common signature for favorable AML.
    Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
    Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
    Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
    Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.